atai Life Sciences to Participate in September Investor Events
September 06 2022 - 6:30PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will participate in the following investor
conferences in September:
- Citi’s 17th Annual
BioPharma Conference in BostonFormat: Industry PanelDate
and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m.
ETConference Link: URL
- H.C. Wainwright’s 24th
Annual Global Investment Conference in New York
CityFormat: Company PresentationDate and Time: Tuesday,
September 13th, 11:00 a.m. ET – 11:45 a.m. ETConference Link:
URL
- Cowen’s 2nd Annual
Novel Mechanisms in Neuropsychiatry Virtual SummitFormat:
Industry PanelDate and Time: Monday, September 19th, 3:05 p.m. ET –
4:05 p.m. ET | 4:15 p.m. ET – 5:15 p.m. ETConference Link: URL
- Jefferies’ 1st Annual
Psychedelics/Emerging Novel Treatments for Mental Health Summit in
New York CityFormat: Company PresentationDate and Time:
Thursday, September 22nd, 9:30 a.m. ET – 10:15 a.m. ETLink:
TBA
The presentations and archived webcasts will also be accessible
in the Events section of atai’s website where they will be
available for up to 90 days.
About atai Life Sciences atai Life Sciences is
a clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. Founded in 2018 as a response
to the significant unmet need and lack of innovation in the mental
health treatment landscape, atai is dedicated to acquiring,
incubating, and efficiently developing innovative therapeutics to
treat depression, anxiety, addiction, and other mental health
disorders.
By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies to achieve clinically meaningful and sustained behavioral
change in mental health patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life
Forward-Looking StatementsThese presentations
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any expressed or
implied statements contained in these presentations that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation, the important factors
described in the section titled “Risk Factors” in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”), as updated by our subsequent filings with the
SEC, as such factors may be updated from time to time in atai's
other filings with the SEC. atai disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by applicable law.
Contact Information
Investor Contact:Stephen BardinChief Financial Officer, atai
Life SciencesEmail: IR@atai.life
Media Contact:Allan MalievskySenior Director, External Affairs
Email: allan@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024